StoxPiramal Pharma vs Acutaas Chemicals: share price & financials comparison
NSE: PPLPHARMA vs ACUTAAS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Piramal Pharma vs Acutaas Chemicals at a glance
Piramal Pharma (PPLPHARMA) has a market capitalisation of ₹31,791 Cr, against ₹31,001 Cr for Acutaas Chemicals (ACUTAAS). Over the past year Acutaas Chemicals has returned +124.2%, compared with +17.2% for Piramal Pharma. Acutaas Chemicals earns a higher return on equity (23.6% vs -2.6%). Piramal Pharma comes out ahead on valuation and technicals. Acutaas Chemicals comes out ahead on size, profitability, growth, financial health and momentum. Across the scored metrics below, Piramal Pharma leads on 4 and Acutaas Chemicals on 10. On StoxGud's 10-point checklist, Piramal Pharma scores 6/10 and Acutaas Chemicals scores 9/10.
| Metric | Piramal Pharma | Acutaas Chemicals |
|---|---|---|
| Size | ||
| Market cap | ₹31,791 Cr | ₹31,001 Cr |
| Revenue (latest FY) | ₹8,869 Cr | ₹1,339 Cr |
| Net profit (latest FY) | ₹-326 Cr | ₹356 Cr |
| Valuation | ||
| P/E | — | 70.6 |
| P/B | 3.90 | 16.69 |
| Dividend yield | 0.06% | 0.04% |
| Profitability | ||
| Return on equity | -2.6% | 23.6% |
| Net profit margin | -2.1% | 27.6% |
| Operating margin | 12.3% | 39.1% |
| Growth | ||
| Revenue growth (YoY) | +28.1% | +42.7% |
| Net profit growth (YoY) | — | +73.3% |
| Revenue CAGR (multi-year) | +7.8% | +26.7% |
| Financial health | ||
| Debt to equity | 0.70 | 0.00 |
| Momentum | ||
| 1-month return | +17.9% | +19.3% |
| 1-year return | +17.2% | +124.2% |
| 3-year CAGR | +30.2% | +87.5% |
| 5-year CAGR | — | +48.9% |
| Distance from 52W high | -0.3% | -5.4% |
| Technicals | ||
| RSI (14) | 76 | 68 |
| Price vs 200-day avg | +33.9% | +31.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Piramal Pharma | Acutaas Chemicals |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Piramal Pharma or Acutaas Chemicals?
Piramal Pharma has a market cap of ₹31,791 Cr and Acutaas Chemicals has a market cap of ₹31,001 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Piramal Pharma or Acutaas Chemicals?
Acutaas Chemicals did better: Piramal Pharma returned +17.2% and Acutaas Chemicals returned +124.2% over one year.
Is Piramal Pharma or Acutaas Chemicals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Piramal Pharma scores 6/10 and Acutaas Chemicals scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.